TapImmune Inc Share Price Nasdaq
Equities
US8760334081
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 37.17M 3.1B |
---|---|---|---|---|---|
Net income 2024 * | -17M -1.42B | Net income 2025 * | -31M -2.59B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3.26
x | P/E ratio 2025 * |
-3.26
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.79% |
Latest transcript on TapImmune Inc
Managers | Title | Age | Since |
---|---|---|---|
Juan Vera
CEO | Chief Executive Officer | 44 | 17/18/17 |
Monic Stuart
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gerald Garrett
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/19/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Norman Eansor
CHM | Chairman | 63 | 17/18/17 |
Steven Elms
BRD | Director/Board Member | 60 | 06/19/06 |
Katharine Knobil
BRD | Director/Board Member | 60 | 08/21/08 |
1st Jan change | Capi. | |
---|---|---|
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+49.62% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
+24.01% | 12.1B |